Warning: This document, and the Academic Journal paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of Nature’s content may be guilty of insider trading under the US Securities Exchange Act of 1934.
PICTURES: While we are happy for images from Neuropsychopharmacology to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).
HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at [email protected], citing the specific example.
PLEASE CITE NEUROPSYCHOPHARMACOLOGY AND THE NEUROPSYCHOPHARMACOLOGY WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO http://www.nature.com/npp
---------------------------------------------------------------
Popular “designer drugs” mimic the effects of Ecstasy in the brain
DOI: 10.1038/npp.2011.304
The neurobiological effects of the widely available “designer drugs” mephedrone and methylone are similar to the illegal drug MDMA, commonly known as Ecstasy, suggests research published online in Neuropsychopharmacology. The new study elucidates the mechanism of action of these compounds, and sheds light on the toxicity and abuse potential of substances that are known by innocuous names such as “bath salts” or “plant food”.
Mephedrone and methylone are structurally related to MDMA and used for personal experimentation, mood elevation and “legal highs”. By performing studies in brain tissue systems and in the brains of conscious rats, Michael Baumann and colleagues found that the action of mephedone and methylone on dopamine and serotonin transporters resembles that of MDMA. The results suggest that neurotransmitter release is similarly evoked by each of the compounds, with a larger magnitude of effect on serotonin compared to dopamine. However, at high doses, the drugs began to produce different effects – in addition to subtle behavioral differences between the test groups, administration of MDMA results in more severe hyperthermia, and MDMA-exposed rats display a long-term depletion of serotonin that was not found in response to either of the designer drugs.
Designer drugs are often available over the Internet and in retail shops, and sold under names that offer few clues about their illicit nature. This research increases public awareness of the potential misuse of these products, and will help to inform future policy decisions regarding their legality.
Author contact:
Michael H. Baumann (National Institute on Drug Abuse, NIH, Baltimore, MD, USA)
Tel: +1 443 740 2660; E-mail: [email protected]
Editorial contact:
Diane Drexler (Neuropsychopharmacology, Brentwood, TN, USA)
Tel: +1 615 324 2371; E-mail: [email protected]
---------------------------------------------------------------------------
PRESS CONTACTS
For media inquiries relating to embargo policy for the journal Neuropsychopharmacology:
Rachel Twinn, Nature London
Tel: +44 20 7843 4658; E-mail: [email protected]
From North America and Canada
Neda Afsarmanesh, Nature New York
Tel : +1 212 726 9231; E-mail : [email protected]
From Japan, Korea, China, Singapore and Taiwan
Mika Nakano, Nature Tokyo
Tel: +81 3 3267 8751; E-mail: [email protected]
------------------------------------------------------------------
About Nature Publishing Group (NPG)
Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.
Focusing on the needs of scientists, Nature (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of Nature research journals and Nature Reviews journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including Nature News and NatureJobs plus access to Nature Network and Nature Education’s Scitable.com.
Scientific American is at the heart of NPG’s newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, Scientific American is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 15 local language editions around the world it reaches over 3 million consumers and scientists. Other titles include Scientific American Mind and Spektrum der Wissenschaft in Germany.
Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.
